Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia.
Adult
Humans
Quality of Life
Antineoplastic Agents, Immunological
/ therapeutic use
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ drug therapy
Inotuzumab Ozogamicin
/ therapeutic use
Immunotherapy
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
/ drug therapy
Antibodies, Bispecific
/ adverse effects
B-cell acute lymphoblastic leukemia
Blinatumomab
Brexucabtagene autoleucel
Immune therapy
Inotuzumab ozogamicin
Tisagenlecleucel
Journal
Blood reviews
ISSN: 1532-1681
Titre abrégé: Blood Rev
Pays: England
ID NLM: 8708558
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
17
11
2022
revised:
27
12
2022
accepted:
18
01
2023
medline:
18
4
2023
pubmed:
3
2
2023
entrez:
2
2
2023
Statut:
ppublish
Résumé
About one-half of adults with acute B-cell lymphoblastic leukemia (B-ALL) who do not achieve molecular complete remission or who subsequently relapse are not cured by current chemo- or targeted therapies. Previously, the sole therapeutic option for such persons was a hematopoietic stem cell transplant. Recently, several immune therapies including monoclonal antibodies, bispecific T-cell engagers (BiTEs), antibody-drug conjugates (ADCs), and chimeric antigen receptor T-cells (CARs) have been shown safe and effective in this setting. In this manuscript, we summarize data on US FDA-approved immune therapies of advanced adult B-ALL including rituximab, blinatumomab, inotuzumab ozogamicin, tisagenlecleucel and brexucabtagene autoleucel. We consider the results of clinical trials focusing on efficacy, safety, and quality of life (QoL). Real-world evidence is presented as well. We also briefly discuss pharmacodynamics, pharmacokinetics, and pharmacoeconomics followed by risk-benefit analyses. Lastly, we present future directions of immune therapies for advanced B-ALL in adults.
Identifiants
pubmed: 36732205
pii: S0268-960X(23)00003-6
doi: 10.1016/j.blre.2023.101042
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Inotuzumab Ozogamicin
P93RUU11P7
Antibodies, Bispecific
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101042Informations de copyright
Copyright © 2023. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of Competing Interest RPG is a consultant to NexImmune Inc. Nanexa Pharma Ascentage Pharm Group and Antengene Biotech LLC, Medical Director of FFF Enterprises Inc.; Partner in AZAC Inc.; Board of Directors of Russian Foundation for Cancer Research Support and Scientific Advisory Board: StemRad Ltd.